← Alle mensen

SP

Sanjay Popat

12 publicaties

Publicaties op Oncologisch.com

Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as Eerstelijns Behandeling for Unresec...
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 20 maart 2026
MTAP: nieuwe inzichten in synthetische letaliteit bij NSCLC?
Journal of Thoracic Oncology · 2026-03
Brief Report: Post Hoc Validation of Platinum Ineligibility in NSCLC From the Fase III IPSOS Study.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2025-12
Brigatinib versus alectinib bij ALK-positief NSCLC na crizotinib: ALTA-2 fase II
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2023-12
Amivantamab plus chemotherapie bij EGFR exon 20 inserties NSCLC: PAPILLON fase III
The New England journal of medicine · 30 november 2023
Brigatinib versus crizotinib bij ALK-positief NSCLC: ALTA-1L definitieve resultaten
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2021-12
Nivolumab plus ipilimumab bij irresectabel mesothelioom: CheckMate 743 fase III
Lancet (London, England) · 30 januari 2021
Brigatinib versus crizotinib bij ALK-positief NSCLC: ALTA-1L definitieve PFS
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 1 november 2020
Afatinib bij NSCLC met ongewone EGFR-mutaties: database van 693 patiënten
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2020-05
Brigatinib versus crizotinib bij ALK-positief NSCLC: ALTA-1L fase III
The New England journal of medicine · 22 november 2018
Nintedanib plus pemetrexed-cisplatine bij maligne pleuramesothelioom: LUME-Meso fase II
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 1 november 2017
Afatinib versus chemotherapie bij NSCLC met veelvoorkomende EGFR-mutaties: eerstelijns fase III
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2016-03